Statement of Continued Cooperation Between FDA and ANVISA
Zika Virus Disease
April 11, 2016
This statement expresses the intent of the United States Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) to offer mutual support and to collaborate to address the public health emergency presented by the Zika virus disease outbreak in the Americas. To execute this goal, FDA and ANVISA will further enhance cooperative efforts with robust scientific and technical exchanges, as well as timely and effective communication. In this spirit of cooperation, openness, and mutual support, FDA and ANVISA are committed to advancing our public health missions and mitigating the negative public health impact of Zika virus disease. To support this collaboration and other activities of mutual interest, FDA and ANVISA will also rely on the attached, established statement of cooperation between the parties.
1. Referred to as the National Health Surveillance Agency of Brazil (ANVISA) in earlier documents.
Cooperative Arrangement to Enhance Activities of Mutual Interest (Issued: November 26, 2012)
Confidentiality Commitment Documents (Issued: September 24, 2010)
The above post is reprinted from materials provided by U.S. Food and Drug Administration. Note: Materials may be edited for content and length.
Disclaimer: DoveMed is not responsible for the adapted accuracy of news releases posted to DoveMed by contributing universities and institutions.